链激酶

院前溶栓组患者是在发病现场，诊断AMI后立即给重组链激酶150万U静脉点滴。

The patients in treatment group were immediately given recombination streptokinase 15 million U by intravenous drip in AMI onset site .

急性缺血性卒中患者，推荐不用链激酶（1A级）。

For patients with acute ischemic stroke , we recommend against streptokinase ( Grade1A ) .

肌球蛋白轻链激酶N端删除载体的构建

Cloning of Deletion Mutated N-terminus cDNA of Myosin Light Chain Kinase

肌球蛋白轻链激酶CaM结合位点突变体对肌球蛋白ATP酶活性的影响

Effects of Calmodulin-binding site mutant of myosin light chain kinase on myosin ATPase activity

急诊应用瑞替普酶、重组链激酶溶栓治疗ST段抬高型心肌梗死临床分析

Comparison of Curative Effect of Reteplase and Recombinant Streptokinase in the Patients with ST-Elevation Myocardial Infarction

基因工程链激酶纯化工艺的研究r-sk与UK在治疗高血压脑出血术后局部应用的疗效评价

Comparative Study of Recombinant Streptokinase and Urokinase to Treat Hypertensive Intracerebral Hemorrhage

重组平滑肌肌球蛋白轻链激酶及ATP结合位点突变体的构建及表达

Construction and Expression of the Recombinant Smooth Muscle Myosin Light Chain Kinase and the ATP Binding Site Mutant

目的观察重组链激酶与尿激酶治疗急性心肌梗死（AMI）的疗效、副作用及缺血再灌注损伤。

Objective : To observe the therapeutic effect , side effects and ischemia-reperfusion injury of the thrombolytic therapy treated with recombinant streptokinase or with urokinase .

肌球蛋白轻链激酶（MyosinLightChainKinase，MLCK）具有激酶活性和非激酶活性，在平滑肌收缩过程中起着关键酶调控的作用。

Myosin light chain kinase ( MLCK ) possesses kinase and non-kinase properties , and both properties play important roles in the regulation of smooth muscle contraction .

通过免疫组化与Western-blot检测肾组织肌球蛋白轻链激酶表达。

The expression of MLCK was analyzed in renal tissue by immunohistochemistry and western-blot methods respectively .

链激酶加超声组4h切口的再出血时间均明显短于单药组1h切口的再出血时间。

The rebleeding times of 4 hours lesions in ultrasound plus streptokinase group were shorter than that of 1 hour lesions in streptokinase alone group .

常用的溶栓药物有：链激酶、尿激酶（urokinase，UK）、重组组织型纤溶酶原激活物（rt-PA）、蚓激酶、巴曲酶、瑞替普酶等，其中以UK最为常用。

Commonly used thrombolytic drugs contant Streptokinase , Urokinase ( UK ), Recombinant tissue type plasminogen activator ( rt-PA ), Vermis kinase , Batroxobin , Reteplase etc , UK in especial .

目的急性心肌梗死（AMI）是心血管急症这一，链激酶（SK）、尿激酶（UK）同属第一代溶栓剂，在我国AMI临床治疗中应用广泛。

Objective Acute myocardial infarction ( AMI ) is an emergency of cardio-vascular system . streptokinase ( SK ) and urokinase ( UK ) are widely used in the treatment for AMI .

基因工程链激酶（r-SK）纯化及其单克隆抗体制备和鉴定

Purification of Recombinant Streptokinase ( r-SK ) and Preparation and Characterization of Anti-r-SK Monoclonal Antibody

肌球蛋白轻链激酶（MLCK）在调节平滑肌细胞收缩过程中具有十分重要的作用。

The myosin light chain kinase ( MLCK ) is important in regulating the smooth muscle contraction .

接受链激酶溶栓治疗的急性心肌梗死患者中初始Q波伴ST段抬高与30d死亡率：HERO-2试验的分析

Initial Q waves accompanying ST-segment elevation at presentation of acute myocardial infarction and 30-day mortality in patients given streptokinase therapy : an analysis from HERO-2

对比分析国产基因重组链激酶和德国链激酶静脉溶栓治疗急性心肌梗塞（AMI）的有效性和安全性。

OBJECTIVE : To compare the efficacy and safety of China made gene recombined Streptokinase ( rSK ) and German made streptokinase ( SK ) in the treatment of acute myocardial infarction ( AMI ) .

链激酶（Streptokinase，SK）是世界上最早发现的纤维蛋白酶原激活剂，也是最早作为临床药品治疗血栓性疾病的溶栓酶。

Streptokinase ( SK ) was discovered as the first plasminogen activator in the world , and it was the earliest clinical agent to cure thrombus .

目的：探讨基因重组链激酶（rSK）对腹腔粘连的预防价值。

Objective : To evaluate the value of recombined - streptokinase ( r - SK ) in the prevention of peritoneal adhesion .

胃肠组织肌球蛋白轻链激酶的的含量：结肠平滑肌MLCK含量空白组最高，模型组明显下降（与空白组比较P0.05），而针刺组较模型组有所上升（P0.05）。

Gastrointestinal tissue contents of myosin light chain kinase : The content of MLCK in colon smooth muscle in blank group is highest , that in model group decreased significantly ( compared to blank group P0.05 ) .

目的：复制支气管哮喘（简称：哮喘）大鼠模型，研究其支气管平滑肌肌球蛋白轻链激酶（MyosinLightChainKinase，MLCK）在哮喘发生发展过程中表达的变化规律；

Objective : To establish the bronchial asthma model in rat ; To investigate the expression of myosin light chain kinase ( MLCK ) in bronchial smooth muscle of asthma rat model and explore the role of MLCK in asthmatic pathogenesis ;

在溶栓治疗中，rt-PA与链激酶、尿激酶相比，溶栓后发生再梗和死亡的比例明显减少（P<0.01）。

The effectiveness of rt-PA was better than that of staphylokinase or urokinase . The incidence of reinfarction and mortality was obviously decreased ( P < 0.01 ) .

重组链激酶以6、30、150万IU／kg的剂量水平给大鼠腹腔注射，观察毒性反应。

Three dose levels of r-SK ( 60000 , 300000 and 1500000 IU / kg ) were given ip to rats for 28 consecutive days respectively to observe the toxicity of r-SK , a similar group served as a control .

肌球蛋白，轻链激酶，克隆号：K36，单克隆抗体。

Myosin , Light Chain Kinase , Clone : K36 , Mab anti .

目的观察同等剂量国产重组葡激酶（r-SAK）、重组链激酶（r-SK）和尿激酶（UK）对兔股动脉血栓的溶栓疗效。

Objective To compare the thrombolytic efficacy of native recombinant staphylokinase ( r-SAK ), recombinant streptokinase ( r-SK ) and urokinase ( UK ) in equivalent doses for femoral artery thrombosis in rabbits .

目的：探讨体外治疗性超声（ETUS）联合半量链激酶的助溶血栓效果。

Objective : To explore the efficacy of half dose of recombined streptokinase ( rSK ) combined with external therapeutic ultrasound ( ETUS ) .

目的观察国产重组链激酶（rSK）对下肢急性深静脉血栓形成的疗效和安全性。

Purpose To evaluate the efficacy and safety of intravenous recombinant streptokinase ( r-SK ) in treatment of patients with acute deep veinous thrombosis of the lower limbs ( ADVT ) .

目的根据现有临床研究评价重组组织型纤溶酶原激活剂（rtPA）与链激酶（SK）/尿激酶（UK）治疗肺血栓栓塞症（PTE）的有效性和安全性。

Objective To pool the data of randomized controlled trials ( RCT ) that compared recombinant tissue-type plasminogen activator ( rt-PA ) with urokinase ( UK ) or streptokinase ( SK ) in human pulmonary thromboembolism ( PTE ) and evaluate the efficacy and safety of different thrombolytics .

目的评价小剂量重组组织型纤溶酶原激活物（r-TPA）与国产重组链激酶（r-SK）治疗急性心肌梗死（AMI）的疗效，并比较二者的差异。

Objective To evaluate the clinical efficacy and safety of intravenous thrombolytic therapy using low dose recombinant tissue plasminogen activator ( r-TPA ) and recombinant strepokinase ( r-SK ) in patients with acute myocardial infarction ( AMI ) .

结论重组链激酶治疗下肢非急性期深静脉血栓形成的早期疗效优于国产尿激酶，但药物不良反应较多。影响改良Bentall手术后早期疗效的危险因素分析

Conclusions The early efficacy of recombinant streptokinase was superior to that of urokinase , but its side effect is also more frequent than the latter . Analysis of Perioperative Risk Factors for Early Outcome after Modified Bentall Operation